Pharmafile Logo

News and Press Releases

Brainomix and Boehringer Ingelheim Advance Strategic Partnership in Pulmonary Fibrosis 

The two companies are broadening their partnership, building on strong results seen in the initial phase which demonstrated e-Lung’s potential to enable earlier diagnosis of progressive pulmonary fibrosis (PPF) Findings...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: May 12, 2026

Brainomix
investors@brainomix.com
First Floor, Seacourt Tower West Way Oxford OX2 0JJ

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

First investigational inhaled ENaC blocker to deliver clinically relevant and statistically significant change in lung function compared to placebo Inhaled therapeutic designed to treat the 10% of people with cystic...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 12, 2026

Enterprise Therapeutics
info@enterprisetherapeutics.com
Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, UK

Integrated DNA Technologies Expands Coralville Manufacturing Footprint to Support Growing Global Demand for MRD Solutions

Expanded footprint delivers speed, scale and customization minimal residual disease (MRD) innovators need without compromising quality Increased production capacity leverages IDT’s highly specialized, high-throughput manufacturing platform. 20 April 2026 --...

Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: April 20, 2026

Integrated DNA Technologies (IDT)
custcare@idtdna.com

SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America

New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform Collaboration aims to expand patient access to cost-effective treatments and reinforces SteinCares’ leadership in biosimilars across...

Category: Biotechnology, Manufacturing and Packing, Other
Posted: March 10, 2026

SteinCares
general@steincares.com
San José, Escazú, Edificio Meridiano 5th floor, Costa Rica

Cytiva expands Fast Trak process development and validation services facility in India

Around 30,000 ft2 center will help biopharma shorten development timelines, reduce risk, and scale with confidence Supports multiple modalities including mAbs, pDNA/mRNA, recombinant proteins, and viral vectors. 25 February 2026 --...

Category: BioManufacturing, Drug Discovery, Manufacturing and Packing, Other, Pharmaceutical
Posted: February 25, 2026

Cytiva
Global Life Sciences Solutions USA LLC 1209 Orange Street Wilmington DE 19801 United States

STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi

European Commission grants approval for Gotenfia, a golimumab biosimilar to Simponi that was developed by Bio-Thera and will be marketed by STADA Launch preparations are underway to bring the second...

Category: BioManufacturing, Drug Discovery, Manufacturing and Packing, Other, Pharmaceutical
Posted: February 13, 2026

STADA
info@stada.de

Lonza’s Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC

License agreement centered around technology enabling dual-payload ADC Unique combination of Synaffix’s exatecan-based technology with Qurient’s CDK7 inhibitor. 25 September 2025 -- Amsterdam, The Netherlands and Seongnam-Si, Korea -- Synaffix B.V.,...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: September 25, 2025

Synaffix
admin.synaffix@lonza.com
Pivot Park, Curie Building Kloosterstraat 9 5349 AB Oss The Netherlands

Outlook Therapeutics Announces NICE Recommendation of LYTENAV (bevacizumab gamma) for the Treatment of Wet AMD

First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD...

Category:
Posted: December 6, 2024

Outlook Therapeutics
info@outlooktherapeutics.com
Outlook Therapeutics, Inc. 111 S. Wood Ave Unit,100 Iselin, NJ 08830

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan disease OKYO is the first company to have an IND application granted by...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 16, 2024

OKYO Pharma
info@okyopharma.com
OKYO Pharma Floor 4, 14/15 Conduit St London W1S 2XJ

Professor V. A. Bumelis opens the Lithuanian Museum of Biotechnology

20 September 2024 – Savaitiskes, Lithuania –The 40th anniversary of the Lithuanian biopharmaceutical industry and science was marked on Monday with the opening of the Lithuanian Biotechnology Museum in the...

Category: Biotechnology, Other
Posted: September 20, 2024

Northway Biotech

Signant Health Appoints 20-Year Life Sciences Veteran Paul Richmond to executive leadership team as chief commercial officer

15 July 2024 – Pennsylvania, US – Signant Health, the leader in evidence generation for modern clinical trials, announced today the appointment of Paul Richmond as chief commercial officer. A...

Category: Clinical Trials, Other, Pharmaceutical
Posted: July 16, 2024

Signant Health
media@signanthealth.com
4000 Chemical Road Suite 300 Plymouth Meeting, PA 19462